行情

ACER

ACER

Acer Therapeutic
NASDAQ

实时行情|Nasdaq Last Sale

1.900
-0.140
-6.86%
盘后: 1.900 0 0.00% 16:00 04/07 EDT
开盘
2.150
昨收
2.040
最高
2.230
最低
1.810
成交量
7.08万
成交额
--
52周最高
28.25
52周最低
1.080
市值
1,919.20万
市盈率(TTM)
-0.6518
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ACER价格均价为9.00,最高价位10.00,最低价为8.00。

EPS

ACER 新闻

更多
  • Acer Therapeutics: EDSIVO Appeal Denied But FDA Door Remains Open
  • Seeking Alpha - Article · 03/25 15:21
  • NGL, PLAY, ACER and APDN among midday movers
  • Seeking Alpha - Article · 03/19 16:45
  • Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDAs Office of New Drugs
  • GlobeNewswire · 03/18 21:05
  • Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
  • GlobeNewswire · 03/18 21:05

所属板块

生物技术和医学研究
-2.89%
制药与医学研究
-0.82%

热门股票

代码
价格
涨跌幅

ACER 简况

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
展开

微牛提供Acer Therapeutics Inc(NASDAQ-ACER)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ACER股票新闻,以帮助您做出投资决策。